JPMorgan Chase & Co. 13D and 13G filings for Regeneron Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-06-05 11:11 am Sale | 2025-05-30 | 13G | Regeneron Pharmaceuticals, Inc. REGN | JPMORGAN CHASE & CO JPM | 4,742,611 4.400% | -803,823 (-14.49%) | Filing |
| 2025-04-22 12:01 pm Sale | 2025-03-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN | JPMORGAN CHASE & CO JPM | 5,546,434 5.100% | -1,673,002 (-23.17%) | Filing |
| 2024-01-25 11:11 am Unchanged | 2023-12-29 | 13G | Regeneron Pharmaceuticals, Inc. REGN | JPMORGAN CHASE & CO JPM | 7,219,436 6.700% | 0 (Unchanged) | Filing |
| 2024-01-25 11:10 am Purchase | 2023-12-29 | 13G | Regeneron Pharmaceuticals, Inc. REGN | JPMORGAN CHASE & CO JPM | 7,219,436 6.700% | 1,118,392 (+18.33%) | Filing |
| 2023-01-11 12:09 pm Purchase | 2022-12-30 | 13G | Regeneron Pharmaceuticals, Inc. REGN | JPMORGAN CHASE & CO JPM | 6,101,044 5.600% | 6,101,044 (New Position) | Filing |